Susquehanna International Group
KRYS icon

Susquehanna International Group’s Krystal Biotech KRYS Stock Holding History

Susquehanna International Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.9M Buy
92,700
+47,500
+105% +$12.6M ﹤0.01% 2001
2025
Q4 		$11.1M Sell
45,200
-68,600
-60% -$14.4M ﹤0.01% 2914
2025
Q3 		$20.1M Sell
113,800
-75,100
-40% -$11.2M ﹤0.01% 2204
2025
Q2 		$26M Buy
188,900
+166,100
+729% +$24.4M ﹤0.01% 1726
2025
Q1 		$4.11M Sell
22,800
-99,700
-81% -$16.8M ﹤0.01% 4024
2024
Q4 		$19.2M Sell
122,500
-190,700
-61% -$33.8M ﹤0.01% 1894
2024
Q3 		$57M Buy
313,200
+199,800
+176% +$38.5M 0.01% 994
2024
Q2 		$20.8M Sell
113,400
-91,100
-45% -$15.3M ﹤0.01% 1679
2024
Q1 		$36.4M Buy
204,500
+74,500
+57% +$10.3M 0.01% 1255
2023
Q4 		$16.1M Buy
130,000
+58,200
+81% +$6.45M ﹤0.01% 2032
2023
Q3 		$8.33M Sell
71,800
-44,800
-38% -$5.47M ﹤0.01% 2787
2023
Q2 		$13.7M Buy
116,600
+74,400
+176% +$7.6M ﹤0.01% 2121
2023
Q1 		$3.38M Buy
42,200
+22,400
+113% +$1.76M ﹤0.01% 4086
2022
Q4 		$1.57M Sell
19,800
-2,200
-10% -$163K ﹤0.01% 5184
2022
Q3 		$1.53M Sell
22,000
-5,000
-19% -$361K ﹤0.01% 5537
2022
Q2 		$1.77M Buy
27,000
+3,500
+15% +$218K ﹤0.01% 5166
2022
Q1 		$1.56M Sell
23,500
-120,700
-84% -$7.53M ﹤0.01% 6031
2021
Q4 		$10.1M Buy
144,200
+6,700
+5% +$390K ﹤0.01% 2705
2021
Q3 		$7.18M Buy
137,500
+126,400
+1,139% +$7.48M ﹤0.01% 3366
2021
Q2 		$755K Sell
11,100
-12,100
-52% -$845K ﹤0.01% 8543
2021
Q1 		$1.79M Buy
23,200
+5,900
+34% +$429K ﹤0.01% 6199
2020
Q4 		$1.04M Buy
+17,300
New +$864K ﹤0.01% 6640

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's KRYS Position: Q1 2026 in Review

Susquehanna International Group increased its Krystal Biotech (KRYS) stake by 384% in Q1 2026, buying an estimated $1.91M and bringing the position to 9,042 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5811.

Susquehanna International Group first reported a position in KRYS in Q4 2018 and has held it in 28 quarters since. The position peaked at $18.1M in Q1 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Susquehanna International Group held 9,042 shares of Krystal Biotech worth $2.34M as of Q1 2026.
  • Susquehanna International Group bought 7,175 Krystal Biotech shares in Q1 2026, an estimated $1.91M.
  • Krystal Biotech made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5811 holding.
  • Susquehanna International Group first reported a position in Krystal Biotech in Q4 2018 and has held it in 28 quarters since.
  • Susquehanna International Group's Krystal Biotech position peaked at $18.1M in Q1 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.